Platelet Rich Plasma in Treatment of Melasma

Assiut University

Status and phase: Unknown; Phase 3

Conditions: Platelet Rich Plasma; Melasma

Treatments: Biological: Platelet rich plasma

Study type: Interventional

Funder types: Other

Identifiers

NCT03308370

ETEPRPM

Details and patient eligibility

About

Melasma is a common acquired disorder characterized by symmetric, hyperpigmented patches with an irregular outline, occurring most commonly on the face. The therapy for melasma has always been challenging and discouraging. Platelet rich plasma has been used over the last several years as an effective treatment in various surgical and medical fields. In recent years, Platelet rich plasma has also started to be used in the field of cosmetology. This study is designed to evaluate the therapeutic effect of platelet rich plasma in melasma.

Full description

Melasma is a pigmentary disorder that can be disfiguring and can cause to significant emotional stresses for sufferers, for which a universally effective treatment is still lacking. Platelet rich plasma is commonly used in dermatology and plastic surgery, especially for treating chronic wounds, ulcers, and burns. The most important contents of platelets are contained in the α-granules. Some of the bioactive substances present in the α-granules include platelet-derived growth factor, transforming growth factor -β1 and -β2epidermal growth factor, and mitogenic growth factors such as platelet-derived angiogenesis factor and fibrinogen.

transforming growth factor -β1 decreases melanogenesis via delayed extracellular signal-regulated kinase activation. The regression of melasma in a 27-years-old woman after injecting platelet rich plasma for skin rejuvenation was observed, but controlled clinical trials are still lacking to confirm this preliminary observation.

Enrollment: 26 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients with melasma 18 years old or more

Exclusion criteria

• Patients less than 18 years.
• Pregnant females and females on oral contraceptive pills.
• Patients with a history of hypertrophic scars or keloids.
• Patients with recurrent herpes infection or with present cutaneous infection and those with facial cancer.
• Patients with blood disorders and platelet abnormalities and chronic liver disease.
• Patients using systemic chemotherapy, anticoagulation therapy and antiplatelet agents.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

26 participants in 1 patient group

Platelet rich plasma

Experimental group

Description:

intradermal injection of 5 ml of autologous platelet rich plasma in the lesional skin of the face of 20 melasma patients every 4 weeks for 3 times

Treatment:

Biological: Platelet rich plasma